A study of the 10-strain pneumococcal conjugate vaccine in rural Kenya demonstrated herd protection. Over a 4-year period following the introduction of the vaccine for infants, coupled with a “catch-up” campaign for all children 12-59 months of age, the incidence of invasive pneumococcal disease (IPD) caused by the strains in the vaccine fell by 100% in infants less than two months of age who were too young to be vaccinated. In adults (≥ 15 years old) the incidence of IPD fell by 81% and in 5-14 year olds the incidence fell by nearly 75%. The chances of unvaccinated persons becoming ill with any strain of the disease also fell significantly – by 87% in infants under two months old, by nearly half (47%) in 5-14 year olds, and by more than one-third (37%) in adults.
Full Citation:
Hammitt, L.L., Etyang, A.O., Morpeth, S.C. et al. 2019. Effect of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya. Lancet. 393.
Title of Article: Effect of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya
Author(s): Hammitt, L.L., Etyang, A.O., Morpeth, S.C. et al
Publication Year: 2019
Publication Name: Lancet
Publication Volume: 393
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/31000194/
DOI (Digital Object Identifier): 10.1016/S0140-6736(18)33005-8
Topics: Health
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Kenya
WHO Regions: Africa